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Soluble oligomers of amyloid b (Ab) play a role in the
memory impairment characteristic of Alzheimer’s
disease. Acting as pathogenic ligands, Ab oligomers
bind to particular synapses and perturb their func-
tion, morphology, and maintenance. Events that
occur shortly after oligomer binding have been inves-
tigated here in live hippocampal neurons by single
particle tracking of quantum dot-labeled oligomers
and synaptic proteins. Membrane-attached oligo-
mers initially move freely, but their diffusion is
hindered markedly upon accumulation at synapses.
Concomitantly, individual metabotropic glutamate
receptors (mGluR5) manifest strikingly reduced
lateral diffusion as they become aberrantly clustered.
This clustering of mGluR5 elevates intracellular
calcium and causes synapse deterioration, re-
sponses prevented by an mGluR5 antagonist. As ex-
pected, clustering by artificial crosslinking also
promotes synaptotoxicity. These results reveal a
mechanism whereby Ab oligomers induce the
abnormal accumulation and overstabilization of a
glutamate receptor, thus providing a mechanistic
and molecular basis for Ab oligomer-induced early
synaptic failure.
INTRODUCTION
Early Alzheimer’s disease (AD) is distinguished by selective
impairment of memory formation. The underlying mechanism
putatively involves synaptic dysfunction and deterioration
caused by soluble amyloid b oligomers, also referred to as
ADDLs (Klein et al., 2001; Selkoe, 2002; Lacor, 2007). Ab
assembly additionally generates the insoluble fibrils found in
Alzheimer’s diagnostic amyloid plaques, which themselves
constitute a source of Ab oligomers (Abo) in transgenic mouse
AD models (Koffie et al., 2009). Abo trigger various pathological
traits associated with AD, such as tau hyperphosphorylation,production of reactive oxygen species, and selective neuronal
death (references in Klein et al., 2007). Significantly for memory
dysfunction, they rapidly alter synaptic plasticity, inhibiting
long-term potentiation (LTP) (Lambert et al., 1998; Walsh et al.,
2002; Townsend et al., 2006) and facilitating long-term depres-
sion (LTD) (Wang et al., 2002; Hsieh et al., 2006; Shankar et al.,
2008).
Abo are gain-of-function pathogenic ligands that bind at
membrane sites localized at particular synapses (Lacor et al.,
2004). Timing of specific responses depends on the concentra-
tion and nature of the oligomers. In as little as 5 minutes,
synthetic oligomers applied at relatively high concentrations
bind at synapses and initiate pathological increases in the tran-
script of memory-related immediate early gene arc (Lacor
et al., 2004). Anomalous spine morphology and depletion of
surface NMDAR occur secondarily (Lacor et al., 2007). Applica-
tion of metabolically produced oligomers at very low concentra-
tions provokes a cofilin- and calcineurin-dependent decrease of
NMDAR activity and dendritic spine number after 5 to 15 days
(Shankar et al., 2007). Synapse loss, induced by Abo in culture
(Lacor et al., 2007) and in transgenic mouse AD models (Koffie
et al., 2009), is thought to result from an initial excitotoxicity
mediated by oxidative stress and increased intracellular Ca2+
(Ca2+i; Cullen et al., 1996; references in Bezprozvanny and Matt-
son, 2008). Abo initially cause increased Ca2+i (Kelly and Ferreira,
2006; De Felice et al., 2007), which later diminishes with synapse
loss (Shankar et al., 2007). Aberrant Ca2+ homeostasis and
neuronal hyperexcitability occur in neurons that are close to Ab
plaques (Kuchibhotla et al., 2008; Busche et al., 2008), poten-
tially involving Abo-induced increased NMDAR responses and
subsequent excitotoxicity (De Felice et al., 2007; Szegedi
et al., 2005).
The specificity of Abo binding requires membrane proteins
that serve adventitiously as toxin receptors. A recently reported
Abo receptor is the cellular prion protein (PrPc). Anti-PrPc anti-
bodies reduce binding of Abo to the plasma membrane and
rescue plasticity in hippocampal slices (Lauren et al., 2009).
Binding of Abo to lipid raft-bound PrPc raises the issue of their
diffusion dynamics in the plasma membrane and the relation
to synaptic physiology (Renner et al., 2009). Synaptic receptors
are stabilized at the postsynaptic membrane by interactions with
a subjacent meshwork of scaffolding proteins. Nevertheless,Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc. 739
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Figure 1. Ab Oligomers Bind to Excitatory
Synapses
(A) Labeling of Homer1b/c (red) and gephyrin (blue)
in neurons incubated for 5 min with b-Abo (500 nM).
b-Abo were labeled with streptavidin (green).
Bar: 2 mm.
(B) Quantification of colocalization between b-Abo
and Homer or gephyrin normalized to the relative
proportion of each kind of synapse (mean ± SEM;
t test, ***p < 0.0001; n = 13 neurites).
(C) Detail of the square indicated in (A) showing in
separate channels the immunoreactivity of Homer
(arrows) and Gephyrin (triangles) and the labeling
of b-Abo (top panels). Bottom panels show merge
images of b-Abo and Homer (left) or Gephyrin (right)
and the triple merging (center). Bar: 1 mm.
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Alteration of mGluR5 Diffusion by Ab Oligomerstheir stabilization is transient and receptors continuously diffuse
in and out of the synaptic membrane (Triller and Choquet, 2008).
Recent data on the dynamics of synaptic components supports
the view of the synapse as a steady-state structure with different
local equilibria that can be tuned to regulate receptor numbers at
synapses (reviewed in Renner et al., 2008). In other words, the
population of extrasynaptic receptors is in equilibrium with the
synaptic one and interference with diffusion exchange rates is
likely to modify synaptic efficacy (Ehlers et al., 2007).
We here propose a mechanism to explain the critical patho-
genic ability of Abo to reach synapses and hinder the distribution
of memory-related receptors. Key results have come from
experiments using single particle tracking (SPT) of Abo labeled
by quantum dots (QDs). We found in cultured mature hippo-
campal neurons that membrane-bound Abo diffuse laterally
and accumulate at excitatory synapses where they create clus-
ters whose sizes increase with time. These pathological clusters
greatly reduce the mobility of the group 1 metabotropic gluta-
mate receptor 5 (mGluR5), which normally diffuses readily in
the plasma membrane (Serge et al., 2002). As a consequence,
mGluR5 aggregates in ectopic signaling platforms and impacts
on calcium signaling and NMDAR amount at synapses. This
effect was mimicked by artificial crosslinking of mGluR5 and
inhibited by a specific antagonist. In hippocampal cultured
neurons from mGluR5 knockout (KO) mice, Abo binding to the
neuronal surface was greatly reduced and the loss of NMDAR
was almost abolished.
RESULTS
Interactions between Abo and the surface membranes of living
neurons were investigated by confocal fluorescence microscopy740 Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc.and by SPT analysis. The focus was on
lateral diffusion properties of Abo and
different receptors for neurotransmitters
shortly after Abo attachment to cells
(incubation times of up to 1 hr). Experi-
ments used mature cultured hippocampal
neurons [21–27 days in vitro (DIV)]
and biotinylated (b-Abo) or fluorescent
Abo prepared using methods previouslydescribed for unmodified Abo (Klein, 2002). Such preparations
are known to contain no fibrillar or protofibrillar assemblies
and the oligomers that are present partition by HPLC into two
fractions, with peaks near 60 kDa and 13 kDa (Chromy et al.,
2003). The larger oligomers, previously shown to bind promi-
nently to synaptic spines (Lacor et al., 2004, 2007), were ob-
tained by cutoff filters (50 kDa) and used in most experiments
described below (although, as noted, experiments with the
smaller species suggested certain parallel properties). Fraction-
ated or unfractionated oligomers all yielded predominantly
tetramers, trimers, and monomers by SDS-PAGE (Figure S1A,
available online). Larger oligomers, when initially prepared
in vitro, thus are stable in aqueous buffer but break down into
smaller species in the presence of SDS. As previously shown,
these oligomers do not generate fibrils during incubation with
neurons (Lacor et al., 2004). Abo bind to the surface of neurons
in a saturable dose-dependent manner (Figures S1B1–S1B2).
Ab Oligomers Progressively Form Clusters
at the Cell Surface
Confocal immunofluorescence microscopy has shown that Abo
cluster at synapses labeled with PSD95, NR1, and CaMKII
(Lacor et al., 2004, 2007). We determined that their biotinylated
counterparts (b-Abo), detected by fluorescently labeled strepta-
vidin, also preferentially associate with synapses. b-Abo colocal-
ized with Homer1b/c, a scaffolding protein concentrated at
excitatory synapses that interacts with metabotropic glutamate
receptors and members of the Shank family (Tu et al., 1999;
Figures 1A–1C). On the contrary, b-Abo showed little colocaliza-
tion with the scaffolding protein of inhibitory synapses, Gephyrin,
indicating the selective binding of Abo to excitatory synapses
(Figures 1A–1C).
EA
G
to
ta
l i
nt
en
si
ty
 (a
.u
.)
100 nM TAMRA-Aβ oligomers 
1 min
+ 2 min + 5 min + 10 min 
*** ***
+ 1 min + 0 min 
***
***
0
2
4
1
3
CB
5 15 60
to
ta
l i
nt
en
si
ty
 (a
.u
.)
0
1
2
3
4
5
***
***
time (min)
ar
ea
 (p
x2
)
time (min)
0
5
10
15
5 15 60
***
***20
Merge FM4-64b-Aβo 500 nM 5 min 
+0 min +2 min +5 min +10 min
F
TAMRA-Aβo 100 nM 1 min Synapsin Merge 
D
5 min 60 min
av
er
ag
e 
in
te
ns
ity
 (a
.u
.)
out in0
1
2
3
4
out in
ns
**
Figure 2. Ab Oligomers Are Recruited in Aggregates by Means of Lateral Diffusion
(A) Labeling of b-Abo (left) and synapses (FM4-64; middle) in living neurons after 5 min of b-Abo application (500 nM). Right image shows the merging of both.
Bar: 1 mm.
(B and C) Time dependence of b-Abo cluster surface area (B) and total intensity (C) (mean ± SEM; 30 neurites; t test, ***p < 0.0001).
(D) b-Abo average intensity at (in) or outside (out) synapses (mean ± SEM; 30 neurites; t test, **p < 0.01).
(E) Immunostaining of synapsin (middle) in neurons treated with TAMRA-Abo (100 nM; left) for 1 min. Right image shows the merging of both. Bar: 1 mm.
(F and G) TAMRA-Abo were applied for 1 min (100 nM) and neurons were observed at the indicated times after rinsing. Note that TAMRA-Abo cluster fluorescence
intensity increases progressively (quantified in G) even if there are no more oligomers in the cell medium. Bar: 1 mm.
(G) Quantification of TAMRA-Abo fluorescence intensity (box: median, 25%, and 75% interquartiles; n = 676–2382 clusters; MW, ***p < 0.0001).
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Alteration of mGluR5 Diffusion by Ab OligomersIn living neurons labeled with FM4-64 to identify active
synapses, b-Abo formed clusters comparable to those seen in
fixed cells, with 50% colocalizing or closely apposed to
synapses (Figure 2A). The clusters became larger with increasing
times of application (up to 60 min, t test p < 0.0001; Figure 2B),
and their total fluorescence intensity increased nearly 4-fold
(1.27-fold between 5 and 15 min and 3.73-fold between 5 and
60 min; t test p < 0.0001; Figure 2C). The fluorescence increase
was more important at synaptic clusters (20% more than at
extrasynaptic clusters after 60 min, t test p < 0.009; Figure 2D).Because use of streptavidin to visualize the oligomers might
potentially induce clustering, we also used Abo coupled to
tetramethyl-rhodamine (TAMRA-Abo). Binding of TAMRA-Abo
gave the same oligomer distribution as seen with streptavidin
(Figures S1C and S1D) and had similar synaptotoxicity (data
not shown). In a ‘‘pulse-chase’’ experiment, TAMRA-Abo was
applied for 1 min at 100 nM. After 1 min of incubation, the
TAMRA-Abo had already formed clusters (Figure 2E) and
50% of these clusters were associated with synapsin-stained
presynaptic boutons. Observations from 1 to 10 min revealedNeuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc. 741
Table 1. Median D Values of mGluR5 or Abo
Median D Extrasynaptic Synaptic
(102 mm2$sec1) mGluR5 Abo mGluR5 Abo
Control (n) 14.48 (900) n/a 1.48 (368) n/a
5 min with 20 nM Abo (n) 9.97 (260)** 3.41 (279) 1.80 (65)ns 2.35 (191)
5 min with 500 nM Abo (n) 2.02 (597)*** 0.86 (713) 1.17 (221)* 1.02 (609)
15 min with 20 nM Abo (n) n/d 1.91 (264) n/d 1.30 (327)
60 min with 20 nM Abo (n) 1.03 (413)*** 0.95 (171) 0.89 (190)*** 1.07 (176)
60 min with 500 nM Abo (n) 0.89 (577)*** 0.41 (195) 0.95 (241)*** 0.41 (181)
Summary table of median D values of mGluR5 or Abo, in neurons in control conditions or treated with 20 nM or 500 nM Abo. Controls correspond here
to cells incubated for 60 min with the control solution (similar values were obtained when they were incubated for 5 min). Numbers in parentheses are
the total number of trajectories. KS test, *p < 0.05, **p < 0.01, ***p < 0.0001. n/a, not applicable. n/d, no data; ns, not significant.
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Alteration of mGluR5 Diffusion by Ab Oligomersthat the fluorescence intensity of TAMRA-Abo clusters increased
progressively (Figures 2F and 2G). Their fluorescence was
monitored after rinsing the neurons; therefore any change in
the surface clustering of TAMRA-Abo can only result from their
reorganization by means of lateral diffusion.
Ab Oligomers Show Time-Dependent Reduction
of Lateral Diffusion
The physical properties of b-Abo lateral diffusion were analyzed
with SPT. Neurons were first treated with 500 nM b-Abo for 5 or
60 min and then incubated with streptavidin-coupled QDs
(Bannai et al., 2006; Figures S2A and S2B). Synapses were
identified by labeling with FM4-64. QD labeling did not alter
b-Abo distribution between synaptic and extrasynaptic regions
(50% colocalized or apposed to FM4-64-positive puncta;
Figures S2C and S2D). Single QDs, identified by their blinking,
were detected with a pointing accuracy of 10–20 nm (Dahan
et al., 2003). The movements of QD-bound Abo (QD-Abo) were
tracked and their trajectories were reconstructed from 7.5 s
stream recordings at 33 Hz (Figure S2B). The portions of
trajectories that colocalized with FM spots were defined as
synaptic. The diffusion coefficient D was derived from the initial
slope of the mean square displacement (MSD) versus the time
interval t plot (MSD = 4Dt). In our study, particles with D <
104 mm2$sec1 were defined as immobile (<5% at both extra-
synaptic and synaptic locations) and not analyzed further. The
mean diffusive behavior, free or confined, was deduced from
the shape of the average MSD versus t curve. The trajectories
of molecules diffusing with free (‘‘Brownian’’) diffusion display
an MSD function that depends linearly on t, while in case of
confined motion it reaches a plateau (references in Triller and
Choquet, 2008).
Lateral diffusion of QD-Abo bound to plasma membranes was
not constant, but decreased with time of exposure [60 min with
respect to 5 min; Kolmogorov-Smirnov (KS) test, p < 0.0001 for
trajectories outside as well as inside synapses; Table 1 and
Figure 3A]. In harmony with these measurements, the MSD plots
indicated a marked reduction in QD-Abo mobility (Figure 3B).
The clusters of b-Abo also displayed small movements with
values of D one or two orders of magnitude smaller than
individual QD-Abo (median D, 5 min: 4.85 3 104 mm2$sec1,
n = 856; 60 min: 5.19 3 104 mm2$sec1, n = 1615). Neurons
treated with b-Abo at low concentration (20 nM) gave results742 Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc.analogous to those observed at 500 nM. An initial rapid diffusion
dropped substantially by 60 min, both at extrasynaptic and
synaptic sites (Figures 3C and 3D and Table 1), and the MSD
plot displayed a similar time-dependent increase in confinement
(Figures 3E and 3F). The SPT analysis together with the confocal
fluorescence data imply that b-Abo, bound to molecules
diffusing in the membrane, undergo greatly decreased mobility
as they accumulate within growing clusters. Interestingly, when
low concentration b-Abo were applied only briefly (5 min), anal-
ysis 1 hr later revealed that diffusion outside synapses was still
high (5 + 60; median D: 3.083 102 mm2$sec1, n = 107; Figures
3C and 3D). In contrast, oligomers inside synapses showed
reduced mobility (median D: 0.91 3 102 mm2$sec1, n = 96)
as found with continuous application, suggesting that synaptic
oligomers are more stabilized than the extrasynaptic ones.
We also investigated the characteristics of low-molecular-
weight forms of Abo (LMW-Abo; <50 kDa). As with prior immuno-
fluorescence observations (Lacor et al., 2007), LMW-Abo were
almost undetectable by streptavidin labeling (data not shown).
However, it was possible to observe the nonabundantly bound
LMW-Abo by SPT, due to the higher sensitivity of this technique
(Triller and Choquet, 2008). QD-LMW were found to diffuse faster
than high-molecular-weight forms of Abo (HMW-Abo; >50 kDa)
both inside and outside synapses (Figures S2E and S2F). Indeed,
LMW-Abo applied for 5 min at low concentration diffused
similarly to any transmembrane protein at synaptic as well as
at extrasynaptic locations. However, both high- and low-molec-
ular-weight fractions were slowed down by increasing their
concentration and/or the incubation length (Figures S2E and
S2F). The possibility that these conditions foster reorganization
of LMW-Abo into larger oligomers cannot be ruled out. Overall,
as expected in a diffusion process, the clustering of b-Abo
depends on the concentration and time of application; therefore,
at low concentrations of oligomers more time is required to
establish clusters.
Ab Oligomers Redistribute mGluR5
The observed time-dependent reduction in Abo mobility
suggests their binding would alter the distribution and reduce
the mobility of their associated proteins. There are a number of
synaptic membrane molecules with which Abo potentially
interact. Several receptors and scaffolding proteins coimmuno-
precipitated with Abo in a detergent-stable complex released
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Figure 3. Ab Oligomers Diffusing Laterally
in the Plasma Membrane Are Slowed Down
by Their Clustering
(A and B) Influence of incubation time on lateral
diffusion properties of Abo.
(A) Diffusion coefficient D for trajectories at (in) and
outside (out) synapses after 5 min (blue boxes) or
60 min (white boxes) of Abo application (median,
25%, and 75% interquartiles; KS test, ***p <
0.0001).
(B) Averaged MSD (mean ± SEM) plot for the same
trajectories analyzed in (A), extrasynaptic (solid
lines) or synaptic (broken lines).
(C and D) Diffusion coefficient D at extrasynaptic
(C) and synaptic (D) membranes after continuous
(5, 15, and 60 min) or pulsed (5 min and observed
at 60 min; 5 + 60) b-Abo application at low concen-
tration (20 nM). Note that D decreases with incuba-
tion time and pulsed treatment has an effect only
at synapses (median, 25%, and 75% interquar-
tiles. KS test, **p < 0.01, ***p < 0.0001).
(E and F) Averaged MSD (mean ± SEM) plot of the
trajectories analyzed in (C) and (D) for times of
treatment 5, 15, and 60 min.
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Alteration of mGluR5 Diffusion by Ab Oligomersfrom synaptosomes (Figure 4A1); notably NMDAR subunits NR1
and NR2 and mGluR5 receptors. Consistent with this coimmu-
noprecipitation, an antibody against the extracellular termini of
mGluR5 decreased the binding of Abo to neurons (42% reduc-
tion of fluorescence of Abo puncta; Figure 4B1, ANOVA, p <
0.001), whereas antibodies directed against mGluR1 or mGluR2
had no effect (Figure 4B1). This reduction was dose dependent
(Figure S3A) and occurred over a range of Abo concentrations
(31.25–500 nM; Figure S3B). No effect was seen after the preab-
sorption of antibody with a control antigen peptide (Figure S3C).
Previous reports have shown similar inhibition of Abo binding
using antibodies raised against NR1 (De Felice et al., 2007)
and PrPc (Lauren et al., 2009). Interestingly, incubation of
neurons with combinations of antibodies did not increase the
inhibition in comparison to the effect of individual antibodies
(Figure S3C). This suggests that mGluR5, PrPc, and NR1 may
be in proximity to each other as well as the Abo binding site.
Finally, the binding on hippocampal neurons cultured from
mGluR5/ and mGluR5+/ mice was reduced in a gene
dosage-dependent manner to 19% and 47%, respectively,Neuron 66, 739–7compared to wild-type mice (Figure 4B2
and Figure S3D), indicating that mGluR5
is implicated in the binding of Abo.
To investigate whether Abo may redis-
tribute mGluR5s in cultured hippocampal
neurons, we first measured the associa-
tion of mGluR5 with oligomers in a
Triton-resistant, DOC-extractable frac-
tion. This approach was developed previ-
ously to obtain signal transduction com-
plexes coupled to the spine cytoskeleton
(Husi and Grant, 2001). Proteins were
obtained from mature neurons incubated
with different concentrations (52, 125,and 300 nM) of Abo for 5 or 60 min (Figure 4A2). Western blot anal-
ysis showed a large increase of mGluR5 in the Triton-resistant
fraction at 60 min, thus establishing the oligomer-dependent relo-
cation of this receptor. A proportional relationship between
mGluR5 receptors and oligomers was observed (linear regression
r2 = 0.90; data not shown), consistent with their coaccumulation.
The nature of the domain-comprising association of mGluR5
and Abo was investigated using neurons transfected with a
construct of mGluR5a tagged with Venus at its C terminus
(mGluR5-Ve; Perroy et al., 2008). Without Abo, mGluR5-Ve
was equally dispersed between spines and dendritic shafts.
The addition of HiLyte555-tagged Abo (Hi-Abo) promoted
accumulation of mGluR5-Ve at dendritic spines. Fluorescence
of the receptor was enriched in spines 1.3 and 2.5 times after 5
and 60 min, respectively (mean ± SEM; n = 194–776 spines on
25–43 cells; t test, p < 0.0001; Figures 4C and 4D1). The enrich-
ment of mGluR5-Ve in spines was accompanied by increased
Hi-Abo fluorescence intensity (Figure 4D2 and Figure S3E).
Triple-label immunochemistry verified oligomer-induced
recruitment of mGluR5 to synapses (Figures 4E–4G). Treatment54, June 10, 2010 ª2010 Elsevier Inc. 743
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Figure 4. Ab Oligomers Increase the Clus-
tering of mGluR5 and Its Localization at
Synapses
(A1) Coisolation of selected synaptic proteins from
synaptosomes treated with Abo (A) or vehicle (V)
labeled with anti-Abo (NU-2) and immunoprecipi-
tated with anti-mouse IgG Dynabeads (S, total
synaptosome protein; V and A, eluted fractions).
(A2) Western blot depicting the mGluR5 immuno-
reactivity in Triton-resistant DOC extractable
fraction of neurons treated with Abo at various
concentrations (52, 125, and 300 nM) for 5 or
60 min.
(B1) Abo total intensity in neurons preincubated
with antibodies raised against an extracellular
epitope of mGluR5 (mGR5), mGluR1 (mGR1), or
mGluR2 (mGR2) prior to a treatment with 500 nM
FAM-Abo (mean ± SEM; n = 25–50 dendritic
regions; ANOVA, **p < 0.001).
(B2) FAM-Abo total intensity in neurons from
wild-type (WT), heterozygous (+/), or homozy-
gous (/) mGluR5 KO mice (mean ± SEM;
n = 64–175 dendritic regions; ANOVA, ***p < 0.001).
(C) Fluorescence of Venus-tagged mGluR5a
(mGluR5-Ve; green) in control neurons or after 60
min of application of HiLyte555-tagged Abo (Hi-
Abo; red). Bar: 2 mm.
(D1 and D2) Quantification of enrichment of
mGluR5-Ve (D1) or total intensity of Hi- Abo (D2)
in spines in control (No Abo) or Hi-Abo-treated
neurons (Abo 5 or 60 min; median, 25%, and
75% IQR and 5%–95% confidence intervals;
n = 194–776 spines on 25–43 cells; t test,
***p < 0.0001).
(E1–E3) Immunostaining of mGluR5 (top line) and
synapses (vGluT1; middle line) in control (E1) or
Abo-treated (E2 and E3) neurons (b-Abo 60 min;
500 nM). b-Abo and mGluR5 staining were per-
formed in nonpermeabilizing conditions. Arrows
indicate synaptic mGluR5 clusters. Bar: 2 mm. (E1
and E2) Bottom line shows the merging of mGluR5
(red) and vGluT1 (blue). (E3) (Top) Merging of
mGluR5 (red) and b-Abo (green). (Center) Merging
of b-Abo (green) and vGluT1 (blue). (Bottom) Triple
merging. Right column shows the magnification of
the area indicated by the white rectangle. Triangles
indicate mGluR5 clusters that colocalize with
b-Abo outside synapses.
(F) Quantification of total intensity of mGluR5 in the
absence of b-Abo (no b-Abo) or after continuous
(5 or 60 min) or pulsed (5 min observed at 60 min;
5 + 60) b-Abo application (mean ± SEM; n = 25–
50 cells; t test, **p < 0.001, ***p < 0.0001; ns, not
significant).
(G) Colocalization of mGluR5 and vGluT1 immuno-
reactive clusters in the same conditions as in (F)
(mean ± SEM; n = 25–50 cells; t test, ***p < 0.0001).
Neuron
Alteration of mGluR5 Diffusion by Ab Oligomerswith b-Abo did not prevent the binding of an antibody targeting
an extracellular epitope of mGluR5 (Figure 4E). By 5 min, clus-
ters of b-Abo and mGluR5 already showed a large degree of
colocalization (44.63% ± 4.30%). This colocalization increased
further by 60 min (60.06% ± 1.67%; n = 10 cells; t test,
p = 0.001). The fluorescence intensity of mGluR5 clusters also744 Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc.increased in response to oligomer application [control: 460 ± 54
arbitrary units (a.u.), 5 min b-Abo: 592 ± 21 a.u., 60 min b-Abo:
748 ± 30 a.u.; t test, p = 0.008 and p < 0.0001, respectively;
Figure 4F]. In these experiments, oligomers were added prior
to fixation and processing for fluorescence microscopy, pre-
cluding any blockade of oligomer binding by the anti-mGluR5.
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Figure 5. Ab Oligomers Decrease mGluR5
Lateral Diffusion
(A) Labeling of b-Abo (left) and mGluR5 (center)
and merging of both (right) in living neurons.
Cells were incubated first with b-Abo for 60 min
(500 nM) and then with anti-mGluR5 (10 min).
Arrows indicate spots of mGluR5 (green) colocal-
ized with b-Abo (red). (Bottom) Higher magnifica-
tion of the area indicated by the white rectangle.
Bar: 1 mm (top) or 0.5 mm (bottom).
(B and C) Diffusion coefficients D for QD-mGluR5
trajectories on extrasynaptic (B) and synaptic (C)
membranes in control cells (black) or after appli-
cation of Abo (b-Abo; 500 nM) for 5 (blue) or
60 (red) min.
(D and E) Averaged MSD (mean ± SEM) plots of
the same trajectories analyzed in (B) and (C) at
extrasynaptic areas (D) and at synapses (E).
Same color coding as in (B) and (C). Note that
the amplitude of the effects depends on the dura-
tion of application.
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Alteration of mGluR5 Diffusion by Ab OligomersSimilar results were obtained using an antibody recognizing an
intracellular epitope (Figure S3F). As expected from the spine
enrichment, there was an increase in the proportion of mGluR5
clusters occurring at synapses, which were labeled with
anti-vGluT1. Only a minority of the mGluR5s were synaptic in
nontreated neurons (35.22% ± 3.11%; Figures 4E–4G), and
this distribution was unaltered by continued incubation with
vehicle solution for b-Abo (at 5 min: 36.13% ± 0.94%; t test,
p = 0.75; at 60 min: 31.56% ± 0.96%; t test, p = 0.13) or by short
exposure to b-Abo (5 min; t test, p = 0.98). However, after 60 min
exposure to Abo, synaptic mGluR5 clusters increased signifi-
cantly (53.69% ± 1.89%; t test, p < 0.0001; Figures 4E–4G). Inter-
estingly, after a 5 min pulse of b-Abo followed by a 60 min lag
before observation, fluorescence intensity of mGluR5 clusters
returned to control values (5 min b-Abo + 60 min without
b-Abo: 432 ± 18 a.u.; t test, p = 0.56; Figure 4F) but localization
of mGluRs was shifted to synapses (49.60% ± 2.18%; t test,
p < 0.0001; Figure 4G). Overall, these data indicate thatNeuron 66, 739–7membrane-bound Abo, by direct or indi-
rect interactions, induce the dynamic
redistribution of mGluR5 receptors to
synapses.
Ab Oligomers Reduce the Lateral
Mobility of mGluR5
We next used SPT to analyze lateral
diffusion of mGluR5, to test whether their
redistribution induced by b-Abo was
associated with a change in receptor
mobility. Treatment with b-Abo did not
prevent the subsequent binding to living
neurons of the anti-mGluR5 antibody
used for SPT (Figure 5A). It was shown
that mGluR5 alternate between periods
of fast and slow lateral diffusion, being
slowed down over Homer clusters (Serge
et al., 2002). As expected, we foundthat the diffusion of extrasynaptic QD-mGluR5 was faster than
that at synaptic sites, identified by FM4-64 (Table 1, KS test,
p < 0.0001). In dual-color SPT experiments, single QD-Abo and
QD-mGluR5 could be seen diffusing together (Movie S1).
Application of b-Abo (500 nM) caused a striking, time-depen-
dent increase in the proportion of slowly moving extrasynaptic
mGluR5s, as indicated by a left shift of the D curve (Table 1
and Figure 5B). This shift in D value was accompanied by a major
decrease in the explored surface area (Figure 5D, MSD plot).
Even though diffusion remained Brownian (determined by the
linear relationship between MSD and time interval), the explored
surface area at 0.3–0.4 s dropped by 90% after 60 min [control:
186 ± 6 3 103 mm2; 60 min: 19 ± 1 3 103 mm2; Mann-Whitney
(MW), p < 0.0001; n = 1782–1731]. After 5 min, the explored
surface area was already reduced by 40% (5 min: 111 ± 5 3
103 mm2; MW, p < 0.0001; n = 1809). The mobility of mGluR5
was also reduced at synapses, although the change was less
drastic given their lower mobility in control conditions at this54, June 10, 2010 ª2010 Elsevier Inc. 745
Table 2. Effect of Abo on the Lateral Diffusion of Receptors
Median D Vehicle 60 min Abo
(102 mm2$sec1) extrasyn syn extrasyn syn
mGluR5 (n) 14.48 (900) 1.48 (368) 0.89 (577)*** 0.95 (241)***
AMPAR (n) 7.80 (518) 0.57 (153) 7.19 (170)ns 1.08 (156)ns
GABAR (n) 13.83 (210) 2.39 (157) 10.92 (345)*** 3 (236)*
Median D values of the different receptors in control conditions (vehicle)
or after 60 min of Abo application (500 nM) at (syn) or outside (extrasyn)
synapses. Numbers in parentheses are the total number of trajectories.
KS test, *p < 0.05, ***p < 0.0001. ns, not significant.
Neuron
Alteration of mGluR5 Diffusion by Ab Oligomerslocation (Table 1 and Figure 5C). The confinement increased in a
time-dependent manner (Figure 5E) and the explored surface
area decreased from 41 ± 3 3 103 mm2 (control, n = 819) to
23 ± 23 103 mm2 after 5 min (n = 678) and to 1 ± 103 mm2 after
60 min (n = 735; MW, p < 0.0001). Similar results were obtained
with 20 nM b-Abo (Table 1). Overall, our results have shown that
the progressive slowdown of Abo diffusion was paralleled by a
major decrease in mobility of mGluR5s.
The slower diffusion of mGluR5s was coupled with a reduced
exchange of receptors between synaptic and extrasynaptic
locations. In control conditions, 70%–75% of synaptic recep-
tors were exchanged during the recording period. After 60 min
of application of b-Abo (500 nM), the exchange was significantly
reduced to 40%–45% (control: 73.43% ± 4.13%; b-Abo 60 min:
43.53% ± 4.77%; t test, p < 0.0001). Decreased escape of
receptors from synapses observed by SPT is consistent with
the increased amount of synaptic mGluR5 seen by immunocyto-
chemistry (see Figures 4D, 4E, and 4G).
In order to see whether the effect is independent from the
labeling sequence, mGluR5 receptors were first labeled with
QDs and observed in control conditions. The anti-mGluR5
antibody was used at a concentration (0.18 mg/ml) that did not
prevent the binding of Abo to cells (Figures S3A and S4C). After
a sequence of recordings, Abo were added to the medium and
mGluR5 mobility was followed on the same samples for the
following 25 min. Receptors progressively slowed down at extra-
synaptic and synaptic locations (Figures S4A–S4C) and some
QD-mGluR5s were associated with Abo clusters (Figure S4C).
Thus the antibody-QD complex did not prevent the interaction
of Abo with the cell surface or the capacity of oligomers to cause
slowdown and relocation of mGluR5 receptors.
Because the effect of b-Abo on the mobility of mGluR5 could
be due to a nonspecific action of oligomers on the membrane,
we analyzed the lateral diffusion of AMPA-type glutamate recep-
tors (AMPARs) and GABA receptors (GABARs). After 60 min of
incubation, the mobility of AMPARs was not affected (Table 2
and Figures S4D and S4E). GABARs, however, were slowed
down modestly at the extrasynaptic membrane but accelerated
at synapses (Table 2 and Figures S4F and S4G).
Extracellular Scaffolding Alters Distribution
and Mobility of mGluR5
The increased clustering and reduced mobility of mGluR5
caused by b-Abo suggest that the latter could act as an ‘‘extra-
cellular scaffold.’’ Indeed, a similar change in diffusive behavior
could be produced by crosslinking receptors (X-link) using746 Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc.biotinylated antibodies and fluorescent streptavidin (Figure 6A).
Crosslink-induced clusters of mGluR5 increased in fluorescence
intensity with time (5 min: 131 ± 4 a.u.; 60 min: 233 ± 9 a.u.; t test,
p < 0.0001), whereas there was no change in control fixed cells
(Figure 6B). Their localization also was progressively shifted to
synapses (5 min: 60.46% ± 1.86%; 60 min: 70.08% ± 2.04%;
t test, p = 0.002; Figure 6C).
As expected, crosslinking significantly reduced the mobility of
QD-mGluR5 (Figure 6D). The median D of extrasynaptic and
synaptic QD-mGluR5 showed a large time-dependent decrease
(80%–90% by 60 min; Table 3). At the extrasynaptic
membrane, the diffusion remained Brownian but the explored
surface areas dropped significantly (Figure 6E). At synapses,
the crosslinking increased the confinement of mGluR5 in a
time-dependent manner (Figure 6E) and the exchange of recep-
tors was reduced (control: 82% ± 5%; X-link: 50% ± 7%; t test,
p = 0.0006). Specificity was indicated by the unchanged mobility
of AMPAR at extrasynaptic as well as synaptic locations (Figures
S5A and S5B). The results show that the scaffolding effect
produced by crosslinking of mGluR5 recreates the effects of
Abo on the diffusion of receptors.
When crosslinking of mGluR5 was performed on neurons that
were already treated with Abo (nonbiotinylated ones, 20 nM),
subsequent detection of Abo by their antibody was impaired,
but their mobility could still be detected by QD-coupled to anti-
Abo antibody. Importantly, the crosslinking of mGluR5 reduced
the diffusion of QD-Abo at both extrasynaptic and synaptic
locations (Table 3 and Figure 6F). The reduction in mobility was
also reflected on the MSD plot (Figure 6G). The data indicate
that crosslinking of mGluR5 promotes the clustering of Abo,
analogous to the reciprocal effect instigated by Abo.
Prevention of Ab Oligomer-Induced Synaptic NMDAR
(NR1) Loss bymGluR5 Antagonist andmGluR5Knockout
The loss of NMDARs is one of the reported effects of long-lasting
applications (more than 1 hr) of Ab (Snyder et al., 2005) attribut-
able to the presence of Abo (Lacor et al., 2007). In the following
experiments we made use of pure neuron cultures to prevent
side effects caused by the action of Abo on glial cells (Abramov
and Duchen, 2005). As expected, exposure of neurons to b-Abo
(500 nM, 1 hr) reduced the fluorescence intensity of NR1 (Figures
7A and 7C). Most importantly, the Abo-induced NR1 reduction
was abolished when the neurons were pretreated with the
specific mGluR5 noncompetitive antagonist SIB1757 (SIB),
which negatively modulates the effect of agonists (Carroll,
2008; Figures 7A and 7C). In mGluR5 crosslinking experiments,
NR1 was also reduced at synapses and SIB blocked the effect
(Figures 7B and 7D). On the contrary, SIB did not alter the total
fluorescence intensity of mGluR5 or that of Abo clusters (data
not shown). The results show that the Abo-induced clustering
of mGluR5, which is mimicked by the scaffolding effect of
receptor antibody, has important functional consequences,
producing an mGluR5 activity-dependent loss of NR1 immuno-
reactivity from the synaptic membrane. Experiments done on
cultured neurons from mGluR5 KO mice reinforced the notion
that the presence of mGluR5 was involved in the Abo-induced
loss of NMDAR. As previously reported (Wijetunge et al., 2008;
She et al., 2009), mGluR5+/ and mGluR5/ neurons expressed
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Figure 6. Effect of Crosslinking of mGluR5
on Its Distribution and Mobility
(A) Coimmunodetection of mGluR5 (left) and
synapses (vGluT1; center) in control conditions
or after 60 min of crosslinking of mGluR5 with an
anti-mGluR5 antibody (X-link). Right images
show the merging of both. Bar: 2 mm.
(B) Total fluorescence intensity of mGluR5 after
5 min (n = 17 cells) or 60 min (n = 15) of X-link
(mean ± SEM). Neurons were incubated with
streptavidin for the indicated times before (living)
or after (fixed) fixation (mean ± SEM; t test, ***p <
0.0001; ns, not significant).
(C) Percentage of mGluR5 clusters colocalized
with vGluT1 after 5 min (n = 17) or 60 min (n = 15)
of X-link (mean ± SEM). Neurons were incubated
as in (B) (t test, ***p < 0.0001; ns, not significant).
(D) Diffusion coefficient D for mGluR5 trajectories
at (in) and outside (out) synapses in neurons
without (black) or after 5 (blue) or 60 (red) min of
X-link (median, 25%, and 75% interquartiles; KS
test, **p < 0.001, ***p < 0.0001).
(E) Averaged MSD plots of the same trajectories
analyzed in (D) (same color coding as in D) at
(broken lines) and outside (solid lines) synapses.
(F and G) Neurons were treated first with unmodi-
fied Abo (5 min, 20 nM) and mGluR5s were cross-
linked with antibodies and streptavidin for 60 min.
(F) Diffusion coefficient D for Abo trajectories at (in)
and outside (out) synapses in control cells (black)
or after 60 min of crosslinking of mGluR5 (red)
(median, 25%, and 75% interquartiles; KS test,
***p < 0.0001). (G) Average MSD plot of the same
trajectories analyzed in (F) (same color coding as
in F) at (broken lines) or outside (solid lines)
synapses.
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Alteration of mGluR5 Diffusion by Ab Oligomersless NMDAR (24% reduction; Figure 7E), but in mGluR5/
mouse the loss of NR1 was nearly abolished. More precisely,
after 3 hr of treatment with Abo, NR1 labeling was reduced to
20% and 65% of control values on wild-type and mGluR5+/
neurons, respectively, and only to85% on mGluR5/ neurons
(Figure 7E).
Ab Oligomers and mGluR5 Crosslinking Impact
Intracellular Calcium and Network Activity
mGluR5 activity is known to elevate Ca2+i, a response also
induced by Abo in cultured neurons (Kelly and Ferreira, 2006;Neuron 66, 739–7De Felice et al., 2007). We therefore
carried out experiments to test the rela-
tionship between b-Abo and mGluR5
and Ca2+i, using fluorescence intensity
of Fluo-4 AM to monitor Ca2+i levels
(Figures 8A and 8B). The total intensity,
measured on a dendrite near to the cell
body, was averaged during 2 s stream
acquisitions at 5, 10, 15, and 30 min.
Neurons that displayed a spontaneous
increase in Ca2+i (transient or persistent)
were counted as ‘‘responding’’ cells. In
control conditions there were 20%
responding cells during the recorded session. After the addition
of b-Abo (500 nM, 5–30 min) the proportion of responding cells
rose significantly (2.4-fold; Figure 8C). Importantly, this effect
was abolished by an mGluR5 antagonist. When neurons were
pretreated with SIB, the proportion of responding cells remained
similar to that of control cells (Figure 8C). The Abo-associated
Ca2+i increase was time dependent and its amplitude in the
remaining responding neurons was reduced after SIB treatment
(Figure 8E). mGluR5 crosslinking experiments gave similar
results (Figures 8D and 8F). Additionally, incubation with an anti-
body against the extracellular termini of mGluR5, which reduced54, June 10, 2010 ª2010 Elsevier Inc. 747
Table 3. Median D Values ofmGluR5 or Abo in Control Conditions
or after Crosslinking of mGluR5
Median D Extrasynaptic Synaptic
(102 mm2$sec1) mGluR5 Abo mGluR5 Abo
Control (n) 8.91 (284) 3.00 (263) 1.46 (104) 1.51 (167)
5 min X-link (n) 5.75 (169)*** n/d 0.94 (126)*** n/d
60 min X-link (n) 1.13 (447)*** 1.23 (418)*** 0.32 (163)*** 1.00 (396)***
Median D values of mGluR5 or Abo (applied at 20 nM), in control condi-
tions or after crosslinking of mGluR5. Numbers in parentheses are the
total number of trajectories. KS test, ***p < 0.0001. n/d, no data.
Neuron
Alteration of mGluR5 Diffusion by Ab OligomersAbo binding to cells (Figure 4B), counteracted the rise of Ca2+i
after 5 min of Abo application (Figure 8G) and lowered the
proportion of responding cells (Figure 8H). We also found no
additive effects of Abo treatment and crosslinking of mGluR5
on the Ca2+i increase at steady state, i.e., after 15 min of Abo
treatment (compare Figure 8G with Figures 8E and 8F), and the
proportion of responding cells was similar to that of Abo alone
(Figures 8C and 8H). The nonadditivity of mGluR5 crosslinking
and Abo together with the inhibition of Abo effects by anti-
mGluR5 antibody strongly suggest a critical role for Abo-mGluR5
interaction in mediating Abo toxicity.
In a final experiment, the global effect of Abo and the clustering
of mGluR5 on synaptic activity was monitored with FM4-64
unloading. After synapses were loaded with FM4-64, the fluores-
cence decrease was monitored as a function of time following
Abo application (Figures S6A and S6B) or mGluR5 crosslinking
(Figures S6C and S6D). As exemplified (Figures S6A and S6C)
and quantified (Figures S6B and S6D), both treatments
increased the FM4-64 unloading, an effect that was abolished
by SIB. Taken together, the Ca2+i and FM4-64 experiments
suggest that pathological clustering of mGluR5s caused by
Abo or mGluR5 crosslinking induces a network dysfunction
that is preventable by the mGluR5 antagonist SIB.
DISCUSSION
We have investigated membrane protein dynamics following
the initial binding of Abo to neurons. Real-time analysis revealed
three unsuspected events. First, Abo formed clusters at the
synaptic plasma membrane in a manner that was time depen-
dent. The binding was dependant on the presence of mGluR5.
Second, the clustering altered the diffusion properties of
mGluR5 receptors, which were redistributed within the plasma
membrane. Third, and most significantly, the mGluR5 redistribu-
tion promoted an aberrant Ca2+ mobilization and loss of
NMDAR. In essence, the creation of artificial signaling platforms
by Abo provides a mechanistic origin for synaptic chaos, the
progressive dysfunction and degeneration that result in
Alzheimer’s memory loss.
AbOligomersDiffuse Laterally andProgressively Create
Clusters at the Neuronal Surface
Once bound to the membrane, Abo progressively and rapidly
built up clusters by means of lateral diffusion. The increasing
size of the clusters was paralleled by reduced Abo mobility.748 Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc.Comparable recruitment correlated with the reduction of diffu-
sion is known for other membrane molecules including trans-
membrane proteins (Douglass and Vale, 2005). The kinetics of
cluster formation depended on the concentration and time of
application of Abo, as expected for a diffusion-reaction process.
The smaller oligomers, LMW-Abo, applied at low concentration,
diffused first similarly to any transmembrane protein but their
diffusion slowed progressively with time. The effect was more
rapid with HMW-Abo, which also showed markedly higher
overall binding affecting a higher proportion of synapses. We
previously showed that HMW-Abo triggered synaptotoxicity in
24 hr, while LMW-Abo did not (Lacor et al., 2007), suggesting
that a threshold in the amount of synaptic Abo was not reached
with the latter oligomers. The time and concentration depen-
dence demonstrated here reconcile our results with those
obtained by groups using various oligomer preparations (Hsieh
et al., 2006; Shankar et al., 2007, 2008; Glabe, 2008; Lauren
et al., 2009). Internalization of Abo was not seen during the
time course of our experiments, but this does not exclude the
possibility that such a phenomenon may exist after longer
incubation times, as seen by others (Saavedra et al., 2007).
Long times (several hours) of treatment are needed to observe
mitochondrial alterations and the timing depends on the confor-
mation and concentration of Ab (Deshpande et al., 2006).
Interactions of Abo with the plasma membrane are not fully
characterized. Preincubation of neurons with antibodies against
NMDAR (De Felice et al., 2007), PrPc (Lauren et al., 2009), or
mGluR5 (this study) decrease the binding of oligomers to the
neuronal membrane, and Abo might also bind to lipids (Sokolov
et al., 2006). The implication of mGluR5 was further supported by
the reduced Abo binding on mGluR5/ neurons. However, the
binding was not totally abolished. Interestingly, our competition
experiment with a cocktail of antibodies suggests that mGluR5,
PrPc, and NMDAR are in proximity to each other. In fact, group 1
mGluRs are known to be part of large multimolecular complexes
that contain NMDAR and possibly PrPc (Tu et al., 1999; Perroy
et al., 2008; Khosravani et al., 2008).
Ab Oligomers Redistribute mGluR5s and Affect Their
Lateral Mobility
The fact that Abo clusters recruit mGluR5 is of particular impor-
tance. mGluR5 is detected on dendrites mainly outside
synapses. Synaptic mGluR5s form a ring at the periphery of
the postsynaptic density (Lujan et al., 1997) where they are
stabilized by the scaffolding Homer protein. Group 1 mGluRs
are key participants in synaptic plasticity and excitotoxicity.
They modulate NMDAR-dependent LTP and LTD in the hippo-
campus and participate in some forms of NMDAR-dependent
learning (reviewed in Benarroch, 2008). Growing evidence
supports the involvement of mGluR5 in the toxicity of Abo.
mGluR5 has also been reported to be involved in the modifica-
tion of synaptic plasticity by Abo (Wang et al., 2004), and recent
studies have demonstrated that application of metabolically
generated oligomers leads to a ‘‘mGluR-like’’ LTD of AMPARs
(Hsieh et al., 2006). Actually, mGluR5-LTD depends on the
immediate early gene Arc/Arg3.1 (Waung et al., 2008), which is
rapidly elevated after exposure to Abo (Lacor et al., 2004).
mGluR5 also potentiates NMDAR-induced excitotoxicity via a
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Figure 7. Decrease of NMDAR (NR1) at Synapses after Ab Oligomer Treatment or Crosslinking of mGluR5
(A and B) NR1 fluorescence (NR1-IR) in control conditions, after Abo application (A, Abo) or mGluR5 crosslinking (B, X-link) for 60 min. NR1 staining was
performed in nonpermeabilizing conditions. Mean ± SEM. Bar: 2 mm. (A) Note that Abo-associated NR1-IR reduction is prevented by an mGluR5 antagonist
(Abo + SIB). (B) Double immunolocalization of NR1 and vGluT1 in control (B1), after mGluR5 X-link (B2) or after X-link together with SIB (B3).
(C) Quantification of NR1-IR intensity in the experiments illustrated in (A) (control: 118 ± 6 a.u.; b-Abo 60 min: 83 ± 5; b-Abo + SIB: 122 ± 11; t test, **p < 0.01,
***p < 0.001; n = 15 cells).
(D) Quantification of NR1-IR intensity in the experiments illustrated in (B) (control: 110 ± 14 a.u.; X-link 60 min: 76 ± 8; X-link + SIB: 95 ± 4; t test, **p < 0.001,
***p < 0.0001; n = 15 cells).
(E) Quantification of NR1-IR intensity in neurons from wild-type (WT), heterozygous (+/), or homozygous (/) mGluR5 KO mice in control conditions (C) or after
3 hr of incubation with Abo (mean ± SEM; n = 104–605 dendritic regions; ANOVA, *p < 0.05, ***p < 0.001).
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Alteration of mGluR5 Diffusion by Ab OligomersCa2+-activated PP2B/calcineurin activity (Bruno et al., 1995).
Potentiation of NMDAR receptors provides an explanation for
the ability of memantine, which therefore acts downstream
from initiating events, to protect against aspects of Abo toxicity
(Lacor et al., 2007; De Felice et al., 2007). Interestingly, a study
using organotypic cultures of brain slices has shown that calci-
neurin is needed for the synaptotoxicity of Abo (Shankar et al.,
2007). Finally, the second messenger cascade activated by
mGluRs is involved, since oligomers decrease the amount of
phosphatidylinositol diphosphate in a phospholipase C-depen-
dent manner (Berman et al., 2008).Once bound to the membrane, Abo facilitate an increase in
mGluR5 signaling associated with its dynamic redistribution to
synapses. The Abo-induced reduction of mGluR5 mobility was
receptor specific because mobility of AMPARs and GABARs
was not reduced at synapses. If anything, GABAR lateral diffu-
sion was slightly accelerated. This paradoxical effect is probably
related to the change in overall neuronal activity that was
recently shown to underpin calcium-dependent regulation of
inhibitory receptor lateral diffusion (Bannai et al., 2009). The
crosslinking of mGluR5 by extracellular molecules (biotinylated
antibodies and streptavidin) had effects similar to those of Abo,Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc. 749
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Figure 8. Ab Oligomers and Crosslinking of
mGluR5 Impact on Intracellular Calcium
Ca2+i monitored by fluorescence intensity of
Fluo4AM on neurons treated with Abo (A, C, and
E) or after mGluR5 crosslinking (B, D, and F).
Mean ± SEM.
(A and B) Examples of cells (Fluo4 intensity in
pseudo-color).
(C and D) Percentage of ‘‘responding’’ neurons
(that increased Fluo4AM intensity during the
recordings) over control conditions. (C) Neurons
treated with Abo (500 nM) or Abo and SIB (Abo +
SIB; t test, ***p > 0.0001; n = 16–22 fields of obser-
vation). (D) Neurons after mGluR5 X-link or after X-
link and SIB (t test, ***p > 0.0001; n = 15–34 fields
of observation).
(E and F) Fluo4AM fluorescence intensity over time
(F/Fo; mean ± SEM) of cells where the intensity
increased (‘‘responding’’; black symbols) or not
(‘‘not responding’’; white symbols). (E) Cells
treated with Abo (circles) and with Abo + SIB
1757 (squares) (n = 21–105 cells). (F) Cells after
X-link of mGluR5 and without (circles) or with SIB
1757 (squares) (n = 27–127 cells).
(G and H) Neurons were treated for mGluR5 cross-
linking and with Abo (500 nM; X-link + Abo) or they
were incubated with an anti-mGluR5 antibody
prior to Abo application (anti-mGluR5 + Abo). (G)
Fluo4AM fluorescence intensity over time (F/Fo;
mean ± SEM) of responding neurons treated with
mGluR5 X-link + Abo (black triangles) or with
anti-mGluR5 antibody + Abo (white triangles) (n =
44–62 cells). (H) Percentage of responding
neurons treated as in (G) (percentage over control
conditions; t test, p = 0.030; n = 10–20 fields of
observation).
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Alteration of mGluR5 Diffusion by Ab Oligomerssuggesting that the latter act as an extracellular scaffold stabi-
lizing mGluR5 and reducing its lateral diffusion.
Both Abo and artificial crosslinking rapidly recruited mGluR5
to synapses, producing at the same time increased Ca2+i levels.
Later there was a decrease in the number of synaptic NMDAR,
which, as confirmed by experiments on mGluR5/ neurons,
was dependent on the presence of mGluR5. These synaptotoxic
effects were prevented by the mGluR5 antagonist SIB, indicating
a link between mGluR5 redistribution and increased signaling
activity. A protective effect of this drug was also found in slices:750 Neuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc.SIB prevented LTD facilitation but not
LTP inhibition following long-lasting appli-
cation of Abo (Shankar et al., 2008).
Finally, receptors clustered outside
synapses and being activated by gluta-
mate spillover and glutamate release
from astrocytes may also contribute to
the abnormal signaling (Haydon and
Carmignoto, 2006).
Ab Oligomers as Inducers of
Pathological Signaling Platforms
Our data show that the synaptotoxicity
of Abo relies, at least in part, on theircapacity to alter the lateral diffusion of mGluR5 within the plasma
membrane, thereby triggering disruptive signaling activity.
Although the impact is selective for mGluR5 rather than AMPAR
or GABAR, Abo potentially could initiate additional toxic path-
ways by modifying the lateral dynamics of other membrane
proteins. Abo, for example, may also interact with molecules
such as the voltage-gated calcium channel (Nimmrich et al.,
2008), the angiotensin II receptor (Abdalla et al., 2008), or
the acetylcholine receptors (Dougherty et al., 2003; Liu et al.,
2009).
Neuron
Alteration of mGluR5 Diffusion by Ab OligomersCurrent results support the concept that mGluR5 may provide
a better target for pharmacological treatment in AD than
NMDARs, which are downstream in the synaptotoxic pathway.
Additionally, the pathogenic mechanism that we have identified
here implies that identifying compounds that block clustering of
membrane-bound Abo might pave the way for alternative or
complementary therapeutic approaches.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
Hippocampal neurons from 18-day-old Sprague-Dawley rat embryos or P1
pups from mGluR5 KO mice (Xu et al., 2009) were cultured as explained in
the Supplemental Information. In the case of transfection with Venus-tagged
mGluR5a (Perroy et al., 2008), neurons were transfected at 9 DIV using
Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions.
Mature neuronal cultures (21–27 DIV), which have completed synaptic matura-
tion, were used in all experiments. Rats were used in accordance with Animal
Care and Use Committee institutional and national guidelines and regulations
for approved protocols.
Unmodified and Modified Ab Oligomer (ADDL) Preparations
Synthetic Abo were prepared according to published protocols (Supplemental
Information) using unmodified or tagged Ab1-42 peptides: N terminus biotin
tagged (American Peptide) or TAMRA, FAM, or HiLyte555 labeled (AnaSpec).
Unless noted, experiments used b-Abo retained by a 50 kDa cutoff filter. Abo
concentrations indicated refer to Ab monomer equivalent.
Antibodies and Quantification of Fluorescence on Fixed Neurons
The primary antibodies used to recognize post-synaptic densities were
monoclonal anti-gephyrin (mAb7a; Alexis Biochemicals) and polyclonal
anti-Homer1b/c (Synaptic Systems). Abo were detected with monoclonal
NU1 or NU2 (Lambert et al., 2007). mGluR5 was detected using rabbit poly-
clonal antibodies directed against extracellular (Alomone Labs) or intracellular
epitopes (Millipore). AMPAR and NMDAR were detected using mouse mono-
clonal anti-GluR2 or anti-NR1 (BD Biosciences), respectively. Other antibodies
were anti-g2 for GABAR (as in Bannai et al., 2009) and anti-mGluR1 (rabbit
polyclonal; Alomone), anti-mGluR2 (Santa Cruz Biotechnology), monoclonal
anti-streptavidin (Abcam), anti-vGluT1 (guinea pig polyclonal; Millipore), and
anti-synapsin (Synaptic Systems). Secondary antibodies were FITC-, Cy3-,
and Cy5-conjugated goat anti-mouse, anti-rabbit, or anti-guinea pig (highly
cross-reacted; Jackson ImmunoResearch). Alternatively, biotinylated proteins
were detected using Alexa 488-, Alexa 555-, or Alexa 647-conjugated strepta-
vidin (Invitrogen).
Immunocytochemistry experiments are detailed in Supplemental Informa-
tion and in Lacor et al. (2007). The immunolabeling of surface membrane
proteins was performed in nonpermeabilizing conditions. Imaging was
performed on a spinning disk confocal microscope (Leica DM5000B; Leica
Microsystems; spinning disk head, Yokogawa CSU10; Yokogawa) or a Leica
TCS SP2 Laser confocal microscope. The whole systems were driven by
Metamorph software (Molecular Devices). In case of mGluR5-Ve-transfected
neurons, 15–25 regions were chosen on top or outside spines. A stack of
images separated 200 nm in the z axis was taken for each wavelength (Venus
and HiLyte555). Fluorescence was corrected by subtracting background
intensity. Quantification was made choosing the four to five planes with
maximum Venus intensity and averaging the fluorescence of these planes
for each wavelength. The enrichment of mGluR5-Ve in spines was calculated
by dividing the fluorescence intensity of each spine by the mean fluorescence
intensity outside spines on the same cell. In other cases, images were filtered
by segmentation and wavelet transformation (see Supplemental Information)
and quantitative analyses (size and total intensity) of the resulting synaptic
puncta were done using the ‘‘integrated morphometry’’ feature of Metamorph
v7.5. Colocalization and/or apposition between the puncta of two images were
determined using one of the images as a mask. For this purpose, the puncta of
the mask were expanded in one pixel (95 nm).Ab Oligomer Binding
Neurons were incubated for the indicated times with Abo (unmodified, biotiny-
lated, or fluorescently tagged) diluted in culture medium to the indicated
concentrations. Control neurons were incubated with the same amount of
vehicle solution added to the culture medium. Cells were rinsed twice with
MEM recording medium (MEMr; phenol red-free MEM, 33 mM glucose,
20 mM HEPES, 2 mM glutamine, 1 mM sodium-pyruvate, and 13 B27) and
used for SPT or immunocytochemistry experiments. When streptavidin was
used to reveal the localization of Abo, neurons were incubated for 5 min with
the fluorescent streptavidin solution (0.25 mM in MEMr) added immediately
after rinsing. Blocking of Abo hot-spot binding was performed by incubating
neurons for 15 min with 5 mg/ml of antibodies directed to extracellular epitopes
(N-ter) prior to 15 min Abo treatment. Antibodies used were anti-mGluR5,
anti-mGluR1, and anti-mGluR2 or anti-mGluR5 preadsorbed with the control
antigen.
Coisolation of Synaptic Proteins and Ab Oligomers
The coisolation of synaptic proteins and Abo from synaptosomes was
performed as previously described (Lacor et al., 2007; see Supplemental Infor-
mation). The kinetics of mGluR5 and Abo coisolation was investigated in the
Triton-resistant DOC-extractable fraction of hippocampal neurons in cultures.
After treatment of 21 DIV hippocampal cell cultures with Abo or vehicle at
different concentration (52, 125, and 300 nM) for various times (5 and
60 min) at 37C in conditioned media, cells were washed and subsequently
incubated with anti-Abo NU-2. Isolation protocol is detailed in Supplemental
Information. Lysates and immunoprecipitates were analyzed by western blot
using anti-mGluR5 or anti-Abo NU-1.
Crosslinking of mGluR5
In crosslinking experiments, neurons were first incubated with a primary
antibody directed against the extracellular terminus of mGluR5 (100, 7.5 mg/
ml) and then with the corresponding biotinylated F(ab’)2 fragment (10
0; Jack-
son ImmunoResearch). Cells were then incubated with Alexa 488-streptavidin
diluted in MEMr (0.25 mM) for the indicated periods of time. Control neurons
were incubated only with the primary antibody and Alexa 488-streptavidin or
with the primary antibody preadsorbed with the mGluR5 control antigen. No
staining by streptavidin was observed in these conditions.
Quantum Dot Labeling of Ab Oligomers and Receptors
for Single Particle Imaging
Neurons incubated with b-Abo were incubated for 1 min with streptavidin-
coated QDs emitting at 605 nm (0.2–0.3 nM; Invitrogen) as in Bannai et al.
(2006). To track the movement of receptors or unmodified Abo, QDs emitting
at 605 nm conjugated with goat F(ab’)2 anti-rabbit or anti-mouse IgG (Invitro-
gen) were previously coupled with the corresponding primary antibody
directed to extracellular epitopes of the receptors (anti-GluR2, anti-GABA
g2, or anti-mGluR5) or anti-Abo NU1. QDs were incubated first with the anti-
body (6:1 molar ratio, 30 min) and then for an additional 15 min with casein
to block nonspecific binding. Cells were incubated for 10 min at 37C with
the precoupled QDs and rinsed. Synapses were labeled with FM4-64 (15 s
in a solution with FM and 40 mM KCl). All incubation steps and washes were
performed at 37C. Cells were imaged within 30 min after QD staining.
When SPT of Abo was performed after mGluR5 crosslinking, neurons were first
incubated with unmodified Abo (20 nM) for 5 min and then mGluR5 was cross-
linked as described above.
Single Particle Tracking and Lateral Diffusion Analysis
Neurons were imaged in the MEMr at 37C in an open chamber mounted on an
IX70 inverted microscope (Olympus) as described in Renner et al. (2009).
Single QDs were identified by their blinking (Dahan et al., 2003). Synaptic stain
images were filtered by segmentation and wavelet transformation (references
in Renner et al., 2009). Trajectories were defined as synaptic if they colocalized
with a synaptic cluster or if they were in a ‘‘perisynaptic’’ ring of two pixels
(400 nm) around the synaptic cluster. Tracking was performed with
homemade software in MatLab (The Mathworks). The center of the spot
fluorescence was determined by Gaussian fit with a spatial resolution of
10–20 nm. Tracking of Abo clusters was performed identifying them as forNeuron 66, 739–754, June 10, 2010 ª2010 Elsevier Inc. 751
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a given frame were associated with the maximum likely trajectories estimated
on previous frames of the image sequence. Only trajectories with at least 15
consecutive frames were used. The MSD was calculated using MSD(ndt) =
(N  n)1Pi = 1Nn[(xi+n  xi)2 + (yi+n yi)2], where xi and yi are the coordinates
of an object on frame i, N is the total number of steps in the trajectory, dt is the
time between two successive frames, and ndt is the time interval over which
displacement is averaged (Triller and Choquet, 2008). The diffusion coefficient
D was calculated by fitting the first 2 to 5 points of the MSD plot versus time
with the equation MSD(t) = 4D25t + 4sx
2, with sx as the spot localization accu-
racy in one direction (references in Renner et al., 2009). Due to the large
dispersal of values of D, we compared the median values. The explored
surface area between 0.3 and 0.4 s corresponds to the average MSD for the
mentioned intervals. The percentage of exchange was calculated as the
proportion of trajectories that exit synaptic areas at least once during the
recording session.
Ca2+ Imaging
Neurons (pure neuron cultures) were loaded with 0.5 mM Fluo-4 AM for 5 min at
37C in MEMr and incubated for an additional 5 min in imaging medium to
allow complete de-esterification of the intracellular AM esters. Fluo4 AM
fluorescence was monitored before the treatment (time 0) and at 5, 10, 15,
and 30 min after adding the corresponding drugs. When SIB (Tocris) was
used, neurons were incubated for 30 min before the experiment with the
drug diluted in culture medium (3 mM). After the experiments, cells were
labeled with Alexa 555-conjugated streptavidin to assess Abo binding. The
imaging was performed at 37C under an inverted Leica DM-IRB microscope
equipped with a 633 objective (NA 1.32), a cooled CCD camera (CoolSNAP;
Roper Scientific), and appropriate filters (for Fluo4 AM, excitation: 500 ±
20 nm; emission: 535 ± 30 nm; for FM excitation: 535 ± 50 nm, emission:
from 590 nm). At each time point, the image acquisition consisted of a 20 frame
stream recording, which was averaged to obtain one image used for quantifi-
cations. The total fluorescence intensity was measured on one region per cell,
chosen inside a dendrite close to the cell body. The ratio of the fluorescence
intensities in comparison with the initial values (F/Fo) was calculated after
subtraction of the background fluorescence. If the fluorescence increased
more than 10%, the cell was considered as a ‘‘responding’’ cell.
Statistical Analysis and Image Preparation
Unless noted, statistical analyses were done using Prism software (GraphPad
Software) or built-in functions in MatLab using a two-tailed Student’s t test, the
MW, KS, or ANOVA tests (Newman-Keuls or Tukey’s comparison tests). Data
was obtained from at least three independent experiments. Image analysis
was performed using Metamorph software (Molecular Devices) or ImageJ
software (http://rsbweb.nih.gov/ij/). Images were prepared using Photoshop
(Adobe Systems).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one movie, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.neuron.2010.04.029.
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